From unethical experimentation to systematic exclusion, racism has played a terrible role in the development of American healthcare. On this mini-podcast, we discuss how the legacy of clinical trials continues to affect today's research, and share strategies for cancer programs to effectively communicate with underrepresented and marginalized populations.  Guest: Christopher Lathan, MD, MS, MPH, Medical Director, Dana-Farber Cancer Institute at St. Elizabeth's Medical Center; Associate Medical Director, DFCI Network Related Content: Mini-Podcast: Building Trust with Marginalized Groups Building Trust with Patients: Importance of Cultural Competence in Cancer Care Delivery (webcast) Community Outreach to Address Disparities in Cancer Care Eating the Elephant Implementation of a Health Disparities & Equity Program at the Duke Cancer Institute, by Nadine J. Barrett, PhD, MA, MS, et al. Research Review: Making Clinical Trials More Inclusive, Diverse, Accessible, and Representative The views and opinions expressed herein are those of the author(s)/faculty member(s) and do not reflect the official policy or position of their employer(s) or the Association of Community Cancer Centers.

Ver todos los episodios